HAIER BIOMEDICAL(SH:688139) Sou Hu Cai Jing·2025-04-28 12:18Group 1 - The core viewpoint of the news is that Haier Biomedical's stock performance and financial metrics indicate a relatively low valuation compared to the industry average, despite a decline in net profit [1][3]. - As of April 28, Haier Biomedical's closing stock price was 31.02 yuan, down 2.36%, with a rolling PE ratio of 26.90 times and a total market capitalization of 9.863 billion yuan [1]. - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Haier Biomedical at the 64th position in the industry ranking [1][3]. Group 2 - Haier Biomedical focuses on providing comprehensive digital solutions for life sciences and healthcare, targeting pharmaceutical companies, research institutions, and various healthcare users [2]. - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various laboratory automation equipment [2]. - In 2022, Haier Biomedical received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]. Group 3 - For the fiscal year 2024, Haier Biomedical reported a revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit decreased by 9.71% to 367 million yuan [3]. - The company's gross profit margin stands at 47.99% [3]. - The stock's PE ratio is significantly lower than the industry average, indicating potential undervaluation [3].